Novo Nordisk’s Wegovy has been on a winning streak as of late, with a metabolic dysfunction-associated steatohepatitis approval last month and prime position in the oral obesity race.

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide (Wegovy) and Eli Lilly and Co.

WEDNESDAY, Sept. 3, 2025 (HealthDay News) — The weight-loss drug Wegovy may lower the risk of heart attack, stroke or death more than similar medications, according to new research from its maker, Novo Nordisk.

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli Lilly’s blockbuster weight-loss drug.

Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025. The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy (semaglutide) 2.

A recent research from Novo Nordisk suggested that the weight-loss drug Wegovy may reduce the risk of cardiac arrest, death, and stroke.For the study, researchers collected data of more than 21,000 patients with obesity and heart disease but

Novo Nordisk’s popular weight loss drug, Wegovy, is the first and only GLP-1 medication approved to treat metabolic associated steatohepatitis, a serious condition marked by liver scarring. The FDA granted the approval Aug.